Status:
COMPLETED
Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants
Lead Sponsor:
University of New Mexico
Collaborating Sponsors:
National Center for Research Resources (NCRR)
Conditions:
Preterm Infants
Eligibility:
All Genders
7-100 years
Phase:
PHASE2
Brief Summary
Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements. Dosing usually occurs three ...
Detailed Description
Erythropoietin (Epo) increases and maintains hematocrit using once weekly dosing in adults with anemia due to end stage renal disease. Epo is used in preterm infants to treat the anemia of prematurity...
Eligibility Criteria
Inclusion
- \< or = 1,500 grams
- \< or = 32 weeks gestation
- \> or = 7 days of age
- informed consent obtained
Exclusion
- hemolytic disease
- hypertension
- seizures
- thromboses
- major malformation
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01235923
Start Date
April 1 2006
End Date
December 1 2009
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UNM NICU
Albuquerque, New Mexico, United States, 87131